MA31446B1 - Inhibiteurs de raf pour le traitement du cancer de la thyroide - Google Patents

Inhibiteurs de raf pour le traitement du cancer de la thyroide

Info

Publication number
MA31446B1
MA31446B1 MA32420A MA32420A MA31446B1 MA 31446 B1 MA31446 B1 MA 31446B1 MA 32420 A MA32420 A MA 32420A MA 32420 A MA32420 A MA 32420A MA 31446 B1 MA31446 B1 MA 31446B1
Authority
MA
Morocco
Prior art keywords
treatment
thyroid cancer
raf
inhibitor
ptc
Prior art date
Application number
MA32420A
Other languages
English (en)
Inventor
Darrin Douglas Stuart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39749309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31446(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31446B1 publication Critical patent/MA31446B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION CONCERNE L'UTILISATION D'UN INHIBITEUR DE RAF POUR LA FABRICATION D'UNE COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DU CANCER DE LA THYROÏDE, PLUS SPÉCIFIQUEMENT POUR LE CANCER DE LA THYROÏDE PAPILLAIRE (PTC) ; L'UTILISATION D'UN INHIBITEUR DE RAF DANS LE TRAITEMENT DU CANCER DE LA THYROÏDE, PLUS SPÉCIFIQUEMENT DU PTC ; UN PROCÉDÉ DE TRAITEMENT D'ANIMAUX À SANG CHAUD COMPRENANT DES MAMMIFÈRES, SPÉCIALEMENT LES ÊTRES HUMAINS, SOUFFRANT DU CANCER DE LA THYROÏDE, PLUS SPÉCIFIQUEMENT DU PTC, PAR ADMINISTRATION AUDIT ANIMAL EN BESOIN D'UN TEL TRAITEMENT D'UNE DOSE EFFICACE VIS-À-VIS DE LADITE MALADIE D'UN INHIBITEUR DE RAF. L'INVENTION CONCERNE ÉGALEMENT L'UTILISATION D'UN INHIBITEUR DE RAF EN COMBINAISON AVEC UN COMPOSÉ DE PLATINE POUR LE TRAITEMENT DU CANCER DE LA THYROÏDE, DU CANCER DE LA THYROÏDE PAPILLAIRE.
MA32420A 2007-05-23 2009-12-14 Inhibiteurs de raf pour le traitement du cancer de la thyroide MA31446B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93962507P 2007-05-23 2007-05-23

Publications (1)

Publication Number Publication Date
MA31446B1 true MA31446B1 (fr) 2010-06-01

Family

ID=39749309

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32420A MA31446B1 (fr) 2007-05-23 2009-12-14 Inhibiteurs de raf pour le traitement du cancer de la thyroide

Country Status (18)

Country Link
US (2) US20100160381A1 (fr)
EP (1) EP2150252A1 (fr)
JP (1) JP2010528032A (fr)
KR (1) KR20100017894A (fr)
CN (1) CN101674828A (fr)
AU (1) AU2008256922B2 (fr)
BR (1) BRPI0811097A2 (fr)
CA (1) CA2686787A1 (fr)
CL (1) CL2008001492A1 (fr)
IL (1) IL201690A0 (fr)
MA (1) MA31446B1 (fr)
MX (1) MX2009012626A (fr)
NZ (1) NZ580592A (fr)
RU (1) RU2009147291A (fr)
TN (1) TN2009000486A1 (fr)
TW (1) TW200914008A (fr)
WO (1) WO2008147782A1 (fr)
ZA (1) ZA200907250B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
KR20180118141A (ko) * 2016-02-05 2018-10-30 에볼 사이언스 엘엘씨 암 치료를 위한 조합
KR20200037820A (ko) * 2017-08-07 2020-04-09 에볼 사이언스 엘엘씨 암을 치료하기 위한 조합
CN113784713A (zh) 2019-01-11 2021-12-10 纳吉斯制药股份有限公司 白三烯合成抑制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060118472A (ko) * 2003-10-16 2006-11-23 카이론 코포레이션 치환 벤자졸 및 ｒａｆ 키나아제의 저해제로서 그것의 사용
TWI387592B (zh) * 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
CN101679372A (zh) * 2007-03-02 2010-03-24 诺瓦提斯公司 Raf激酶抑制剂的固体形式

Also Published As

Publication number Publication date
US20100160381A1 (en) 2010-06-24
RU2009147291A (ru) 2011-06-27
AU2008256922B2 (en) 2011-07-28
AU2008256922A1 (en) 2008-12-04
JP2010528032A (ja) 2010-08-19
TW200914008A (en) 2009-04-01
WO2008147782A1 (fr) 2008-12-04
NZ580592A (en) 2012-02-24
EP2150252A1 (fr) 2010-02-10
MX2009012626A (es) 2009-12-07
BRPI0811097A2 (pt) 2014-12-09
IL201690A0 (en) 2010-05-31
US20120213867A1 (en) 2012-08-23
ZA200907250B (en) 2010-07-28
CL2008001492A1 (es) 2009-02-20
TN2009000486A1 (en) 2011-03-31
CN101674828A (zh) 2010-03-17
CA2686787A1 (fr) 2008-12-04
KR20100017894A (ko) 2010-02-16

Similar Documents

Publication Publication Date Title
Ceccom et al. Copper chelator induced efficient episodic memory recovery in a non-transgenic Alzheimer’s mouse model
RU2359697C2 (ru) Введение средств для лечения воспаления
MA30085B1 (fr) Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione
Burkey et al. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited
EA201400197A1 (ru) Имидазопиразиновые ингибиторы тирозинкиназы syk
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
PH12014500472A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201000599A1 (ru) Ингибиторы тирозинкиназы брутона
MA32132B1 (fr) Utilisation de ranolazine pour traiter la douleur
MA31497B1 (fr) Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c
MA29326B1 (fr) Combinaison de composes organiques
BRPI0411484A (pt) composto, formulação farmacêutica, métodos de tratamento ou prevenção de distúrbios de lipìdeo (dislipidemia), e de diabetes do tipo 2, uso de um composto, e, composição farmacêutica
MA38144A1 (fr) Compositions et procédés pour le traitement de protéinopathies
PH12014500371A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
MA32056B1 (fr) Suspension pharmaceutique orale contenant du paracetamol et de l'ibuprofene
MA27565A1 (fr) Derives de 4-tetrazolyl-4-phenylpiperidine utilises pour le traitement de la douleur
BRPI0507189A (pt) uso combinado de um agonista de glp-1 e compostos de gastrina
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
DK1664016T3 (da) Terapeutiske midler, der er anvendelige til behandling af smerter
MA62992B1 (fr) Formulations de capsules
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
Li et al. Underlying mechanisms and treatment of acetaminophen‑induced liver injury